Your browser version may not work well with NCBI's Web applications. More information here...
1: Antimicrob Agents Chemother. 2008 Apr;52(4):1545-8. Epub 2008 Jan 28.
Related Articles, Links
Click here to read Click here to read
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.

Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Bénard A, Campa P, Matheron S, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2).

Laboratoire de Virologie, Service de Microbiologie, Hôpital Bichat-Claude Bernard, Paris, France.

We determine phenotypic susceptibility of human immunodeficiency virus type 2 (HIV-2) isolates to amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, saquinavir, and tipranavir. Saquinavir, lopinavir, and darunavir are potent against wild-type HIV-2 isolates and should be preferred as first-line options for HIV-2-infected patients. Other protease inhibitors are less active against HIV-2 than against HIV-1.

Publication Types:
PMID: 18227188 [PubMed - indexed for MEDLINE]

PMCID: PMC2292533